Lateral Flow Immunoassay for CSF Leak Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing cerebrospinal fluid (CSF) leaks are invasive, costly, and lack a quick, reliable, and affordable test for outpatient or postoperative settings, often failing to distinguish CSF from nasal and otologic secretions, which can lead to severe complications if not promptly identified.
Innovation Solution
A semi-quantitative barcode-style lateral-flow immunoassay (LFA) device that detects beta-trace protein (βTP) levels in nasal drip samples, using a porous substrate with specific test lines and indicators to indicate the presence or absence of a CSF leak, providing a rapid and inexpensive point-of-care diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-2 transferrin electrophoresis or ELISA is used for CSF leak detection, then sensitivity and specificity are improved, but cost and time-to-result increase significantly
Solution Approach 1:
The patent extracts the essential detection function from complex laboratory equipment by using a lateral flow assay that detects beta-trace protein specifically in nasal drip samples, eliminating the need for expensive electrophoresis or ELISA equipment while providing rapid results at the point of care
Solution Approach 2:
The patent changes the detection parameter from beta-2 transferrin (requiring electrophoresis) to beta-trace protein (detectable by lateral flow), and specifically analyzes nasal drip samples rather than general CSF samples, enabling rapid detection without compromising accuracy
2Reliability
If imaging techniques such as MRI or CT are used for CSF leak diagnosis, then diagnostic capability is improved, but cost and radiation exposure increase
Solution Approach 1:
The patent employs a disposable lateral flow assay device that is inexpensive, single-use, and provides diagnostic capability without radiation exposure, replacing the need for repeated expensive imaging studies
3Reliability
If operative management is performed for suspected CSF leaks, then definitive treatment is achieved, but patient exposure to anesthesia and surgical risks increases
Solution Approach 1:
The patent enables preliminary diagnostic action through rapid point-of-care testing of nasal drip samples, allowing clinicians to confirm CSF leaks before committing patients to surgery, thereby avoiding unnecessary surgical risks while ensuring treatment is provided to those who truly need it
4Reliability
If traditional diagnostic methods are used, then comprehensive evaluation is possible, but device complexity and operational difficulty increase
Solution Approach 1:
The lateral flow assay device is designed to be self-service, requiring no specialized training or complex equipment operation. The device automatically processes nasal drip samples and provides visual results, making comprehensive CSF leak detection accessible to any clinician in any setting
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LFA device allows for rapid and accurate detection of CSF leaks without expensive equipment or extensive training, enabling timely diagnosis and reducing the risk of complications such as meningitis and brain herniation.
Implementation Method 1
a flow path through which a sample applied to the sample addition zone flows under capillary action away from the sample addition zone into the detection zone
Implementation Method 2
a detection zone where the detection zone comprises at least a first test line (T1) and a second test line (T2) each test line comprising binding moieties that bind a complex formed between beta-trace protein (βTP) and an indicator attached to a βTP binding molecule
Data Source
AI summary
Devices and methods are provided for the detection of CSF in a biological sample. In certain embodiments the device is a lateral flow device comprising: a porous substrate; a sample addition zone disposed on or in said porous substrate; a detection zone disposed on or in said porous substrate where said detection zone comprises at least a first test line (T1) and a second test line (T2) each test line comprising binding moieties that bind a complex formed between beta-trace protein (βTP) and an indicator attached to a βTP binding molecule; wherein said porous substrate defines a flow path through which a sample applied to the sample addition zone flows under capillary action away from said sample addition zone into said detection zone; and wherein said first test line (T1) and said second test line (T2) are is configured so that either no test line signal or just a signal at the first test line (T1) is detectable when βTP concentration in a sample applied to said device is lower than the βTP level indicative of a CSF leak; and said second test line (T2) is configured so that a signal is detectable at said second test line when βTP concentration in a sample applied to said device is greater than the βTP level indicative of a CSF leak.